FDA OKs Vutrisiran for hATTR Amyloidosis With Polyneuropathy

Vutrisiran, an RNAi therapeutic given by subcutaneous injection once every 3 months, significantly improved signs and symptoms of hATTR polyneuropathy in a phase 3 study.
FDA Approvals

Leave a Reply

Your email address will not be published.